AMAG Pharmaceuticals was a biopharmaceutical company focused on developing and commercializing therapeutics primarily in the areas of women's health, maternal health, and iron deficiency anemia. Founded in 1981, AMAG developed and marketed products such as Feraheme® (ferumoxytol injection) for iron deficiency anemia and Makena® (hydroxyprogesterone caproate injection) to reduce the risk of preterm birth in certain at-risk women. In November 2020, AMAG Pharmaceuticals was acquired by Covis Pharma, a global specialty pharmaceutical company backed by Apollo Global Management. Following the acquisition, AMAG's products and operations were integrated into Covis Pharma's portfolio and global infrastructure.
Prior to its acquisition, the Waltham headquarters served as the central command for AMAG's executive leadership, research and development activities, commercial operations, and corporate administrative functions.
The headquarters was located in a modern office park, offering facilities designed to support collaboration and innovation, characteristic of biopharmaceutical companies in the competitive New England biotech cluster.
AMAG aimed to cultivate a patient-centric, innovative, and collaborative work environment, driven by a commitment to addressing unmet medical needs in its therapeutic areas.
The Waltham headquarters was pivotal to AMAG's operations, overseeing the development, approval, and commercialization of its key pharmaceutical products and representing its significant presence in the U.S. biopharma industry.
Prior to its acquisition by Covis Pharma, AMAG Pharmaceuticals' commercial operations were primarily focused on the United States market. However, some of its products, notably Feraheme® (marketed as Rienso® in Europe), had approvals and were available in international markets, including Europe and Canada, typically through licensing and distribution partnerships. Post-acquisition, the global distribution and market access for former AMAG products are managed under Covis Pharma's established global operations network.
1100 Winter Street
Waltham
Massachusetts
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, AMAG Pharmaceuticals' leadership includes:
AMAG Pharmaceuticals has been backed by several prominent investors over the years, including:
AMAG Pharmaceuticals was acquired by Covis Pharma in November 2020 and ceased to operate as an independent, publicly traded entity. Consequently, there have been no executive new hires or exits attributable to 'AMAG Pharmaceuticals' as a standalone company in the last 12 months. Any leadership changes related to former AMAG products or operations would now occur within Covis Pharma's structure.
Discover the tools AMAG Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition by Covis Pharma in 2020, AMAG Pharmaceuticals utilized common corporate email formats. These email formats are no longer in active use for AMAG Pharmaceuticals as an independent entity, and the amagpharma.com domain is not used for ongoing company communications.
[first_initial][last]@amagpharma.com
Format
jdoe@amagpharma.com
Example
0%
Success rate
Business Wire • October 1, 2020
Covis Group S.à r.l. (now Covis Pharma) announced a definitive agreement to acquire AMAG Pharmaceuticals, Inc. for $13.75 per share in cash. The transaction represented an enterprise value of approximately $647 million. This acquisition was intended to strengthen Covis's therapeutic portfolio, particularly in women’s health and anemia management....more
Covis Pharma News • November 12, 2020
Covis Pharma announced the successful completion of its acquisition of AMAG Pharmaceuticals. As a result of the acquisition, AMAG became a privately held company and its common stock ceased trading on the Nasdaq Global Select Market....more
PR Newswire • February 5, 2018
AMAG Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved a broader indication for Feraheme® (ferumoxytol injection) for the treatment of iron deficiency anemia (IDA) in all eligible adult patients who have an intolerance to oral iron or have had an unsatisfactory response to oral iron. This significantly expanded the potential patient population for Feraheme in the U.S....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including AMAG Pharmaceuticals, are just a search away.